Fabian Rossi1,2, Joe Ma3, Nina Tsakadze4,5, Lourdes Benes-Lima4, Julio Araque Gonzalez6, Michael Hoffmann4,5. 1. Department of Neurology, Orlando VA Medical Center, 32827, Orlando, FL, USA. Fabian.Rossi@va.gov. 2. Department of Neurology, University of Central Florida Medical School, 32827, Orlando, FL, USA. Fabian.Rossi@va.gov. 3. Department of Pathology, Director Neuromuscular Department, Florida Hospital, 32803, Orlando, FL, USA. 4. Department of Neurology, Orlando VA Medical Center, 32827, Orlando, FL, USA. 5. Department of Neurology, University of Central Florida Medical School, 32827, Orlando, FL, USA. 6. Department of Neuroradiology, Orlando VA Medical Center, 32827, Orlando, FL, USA.
Abstract
BACKGROUND: Spinocerebellar Ataxia type 2 is a slowly progressive adult onset ataxia with a broad clinical presentation. CASE PRESENTATION: We describe a man with Spinocerebellar Ataxia type 2 with chronic, severe, and recurrent rhabdomyolysis, as part of the cerebellar ataxia genetic spectrum. Initially rhabdomyolysis was refractory to multiple medications, but entirely resolved and remained in chronic remission with pregabalin. CONCLUSIONS: This is the first report of Spinocerebellar Ataxia type 2 associated with chronic, severe, recurrent rhabdomyolysis as part of its genetic phenotype responsive to pregabalin.
BACKGROUND:Spinocerebellar Ataxia type 2 is a slowly progressive adult onset ataxia with a broad clinical presentation. CASE PRESENTATION: We describe a man with Spinocerebellar Ataxia type 2 with chronic, severe, and recurrent rhabdomyolysis, as part of the cerebellar ataxia genetic spectrum. Initially rhabdomyolysis was refractory to multiple medications, but entirely resolved and remained in chronic remission with pregabalin. CONCLUSIONS: This is the first report of Spinocerebellar Ataxia type 2 associated with chronic, severe, recurrent rhabdomyolysis as part of its genetic phenotype responsive to pregabalin.
Authors: A R Paciorkowski; Y Shafrir; J Hrivnak; M C Patterson; M B Tennison; H B Clark; C M Gomez Journal: Neurology Date: 2011-08-31 Impact factor: 9.910
Authors: K Gwinn-Hardy; J Y Chen; H C Liu; T Y Liu; M Boss; W Seltzer; A Adam; A Singleton; W Koroshetz; C Waters; J Hardy; M Farrer Journal: Neurology Date: 2000-09-26 Impact factor: 9.910
Authors: Clara T M M de Kanter; Matthijs van Luin; Caroline Solas; David M Burger; Jan Maarten Vrolijk Journal: Ann Hepatol Date: 2014 Jul-Aug Impact factor: 2.400
Authors: Antonella Antenora; Carlo Rinaldi; Alessandro Roca; Chiara Pane; Maria Lieto; Francesco Saccà; Silvio Peluso; Giuseppe De Michele; Alessandro Filla Journal: Ann Clin Transl Neurol Date: 2017-08-10 Impact factor: 4.511